We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNA Biomarker Distinguishes Growth of Aggressive Prostate Tumors

By LabMedica International staff writers
Posted on 08 Jul 2019
Print article
Image: The serum prostate cancer biomarker prostate-specific antigen (PSA) (Photo courtesy of Wikimedia Commons).
Image: The serum prostate cancer biomarker prostate-specific antigen (PSA) (Photo courtesy of Wikimedia Commons).
A microRNA biomarker found in the urine of men with prostate cancer can distinguish slow growing cancers from potentially life-threatening aggressive tumors.

Current screening tools, including biopsy and blood screening for prostate specific antigen (PSA), are not able to differentiate between the 25% to 40% of patients with slow growing clinically insignificant disease, and the 20% to 35% of patients with aggressive prostate cancer who may not receive appropriate treatment.

Investigators at the University of California, Los Angeles (USA) and collaborators at the University of Toronto (Canada) sought to develop a non-invasive test for the early detection of aggressive prostate tumors and hypothesized that miRNAs in the urine might prove to be appropriate biomarkers for this purpose.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. Furthermore, miRNAs play essential roles in tumor development, are stable under diverse analytical conditions, and can be readily detected in body fluids.

For this study, the investigators measured the longitudinal stability of 673 miRNAs collected from serial urine samples from 10 patients with localized prostate cancer. They then measured temporally stable miRNAs in an independent training cohort and created a biomarker predictive of Gleason grade using machine-learning techniques. Finally, they validated this biomarker in an independent validation cohort.

Results revealed that each individual had a specific urine miRNA fingerprint. These fingerprints were temporally stable, and associated with specific biological functions. Seven miRNAs were identified that were stable over time within individual patients, and these were combined with machine-learning techniques to create a novel biomarker for prostate cancer that overcame inter-individual variability. This urine biomarker robustly identified high-risk patients and achieved similar accuracy as tissue-based diagnostic markers.

"We developed a three-stage experimental strategy that would maximize statistical and data science considerations to give us the best chance of finding a biomarker to predict prostate cancer aggressiveness," said senior author Dr. Paul Boutros, professor of urology and human genetics at the University of California, Los Angeles. "What this test does is gives the clinician, the patient, and their caregivers confidence in their treatment plan."

The study was published in the June 4, 2019, online edition of the Journal of the National Cancer Institute.

Related Links:
University of California, Los Angeles
University of Toronto

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.